Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-0350
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1 ; day:1 ; month:6 ; year:2022 ; pages:1-5
Child's nervous system ; (1.6.2022), 1-5
- Creator
-
Cantor, Evan
Meyer, Ashley
Morris, Stephanie M.
Weisenberg, Judith L. Z.
Brossier, Nicole M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00381-022-05571-y
- URN
-
urn:nbn:de:101:1-2022073110280367037163
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cantor, Evan
- Meyer, Ashley
- Morris, Stephanie M.
- Weisenberg, Judith L. Z.
- Brossier, Nicole M.
- SpringerLink (Online service)
Other Objects (12)
A dose-dependent response to MEK inhibition determines hypoblast fate in bovine embryos
Activation of kappa opioid receptors reduces seizure activity in a dose-dependent way
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
Lymphoproliferative malignancies in patients with neurofibromatosis 1
Analysis of two cases with bronchopulmonary neurofibromatosis
Neurofibromatosis type 1 with three synchronous tumors
Revisiting dandy–Walker malformation with associated neurofibromatosis
Constipation in adults with neurofibromatosis type 1
Kaposiform lymphangiomatosis effectively treated with MEK inhibition
A dose-dependent response to MEK inhibition determines hypoblast fate in bovine embryos
Activation of kappa opioid receptors reduces seizure activity in a dose-dependent way
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
Lymphoproliferative malignancies in patients with neurofibromatosis 1
Analysis of two cases with bronchopulmonary neurofibromatosis
Neurofibromatosis type 1 with three synchronous tumors
Revisiting dandy–Walker malformation with associated neurofibromatosis
Constipation in adults with neurofibromatosis type 1
Kaposiform lymphangiomatosis effectively treated with MEK inhibition
A dose-dependent response to MEK inhibition determines hypoblast fate in bovine embryos
Activation of kappa opioid receptors reduces seizure activity in a dose-dependent way
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists
Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
Lymphoproliferative malignancies in patients with neurofibromatosis 1
Analysis of two cases with bronchopulmonary neurofibromatosis
Neurofibromatosis type 1 with three synchronous tumors
Revisiting dandy–Walker malformation with associated neurofibromatosis
Constipation in adults with neurofibromatosis type 1